C
Conagen
Synthetic Biology And Biological Engineering Company
About Conagen
Founded in 2010 by Dr. Oliver Yu, Conagen is a vertically integrated synthetic biology and biotechnology company. Dr. Yu, the company's CEO, brings extensive experience in metabolic engineering, with a background that includes a Ph.D. from the University of South Carolina, postdoctoral training at DuPont, and a tenure as a Principal Investigator at the Donald Danforth Plant Science Center. His academic and research career, which includes over 120 manuscripts and patents, is foundational to Conagen's scientific approach.
The company operates by using synthetic biology and precision fermentation to manufacture high-value ingredients for a diverse client base. Its business model focuses on providing these bio-manufactured products to companies in the food and beverage, flavor and fragrance, nutrition, pharmaceutical, and renewable materials sectors. Conagen generates revenue by serving these business-to-business markets, leveraging its vertically integrated structure that encompasses everything from initial strain development to commercial-scale production, ensuring speed to market.
Conagen's core service is the development and production of natural products through advanced biological processes. The company engineers microorganisms and utilizes fermentation to create a wide array of molecules, including natural sweeteners, flavors, fragrances, nutraceuticals, and specialty chemicals. Key technological capabilities include strain development, metabolic pathway engineering, and fermentation process development. The company has established proprietary production platforms for major molecular classes like terpenoids, phenolics, and lipids, and uses high-throughput automation and robotics to screen vast numbers of microbial strains efficiently. This bio-manufacturing approach allows for the sustainable and scalable production of ingredients that may be difficult to source through traditional agriculture or chemical synthesis. A significant milestone was a $30 million strategic investment from Sumitomo Chemical in 2020, aimed at accelerating research and developing sustainable chemicals.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Bedford, United States
- Sector
- Food
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Series B and later1 investor entered at this stage
Sumitomo Chemical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Conagen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Conagen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.